Zacks Small Cap Has Negative Outlook for MIRA Q4 Earnings

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Analysts at Zacks Small Cap lowered their Q4 2024 earnings per share estimates for MIRA Pharmaceuticals in a research report issued to clients and investors on Thursday, December 19th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings per share of ($0.29) for the quarter, down from their previous estimate of ($0.19). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share. Zacks Small Cap also issued estimates for MIRA Pharmaceuticals’ FY2026 earnings at ($0.54) EPS.

MIRA Pharmaceuticals (NASDAQ:MIRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04.

Several other analysts also recently commented on the stock. RODMAN&RENSHAW upgraded shares of MIRA Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Rodman & Renshaw started coverage on shares of MIRA Pharmaceuticals in a report on Monday, September 30th. They issued a “buy” rating and a $17.00 target price for the company.

MIRA Pharmaceuticals Trading Down 0.9 %

MIRA stock opened at $1.05 on Monday. The company has a market capitalization of $17.39 million, a P/E ratio of -1.87 and a beta of 1.93. The business has a 50 day simple moving average of $1.36 and a 200-day simple moving average of $1.37. MIRA Pharmaceuticals has a twelve month low of $0.51 and a twelve month high of $5.01.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MIRA Pharmaceuticals stock. Suncoast Equity Management raised its holdings in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 125.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,000 shares of the company’s stock after purchasing an additional 50,000 shares during the quarter. Suncoast Equity Management owned 0.61% of MIRA Pharmaceuticals worth $117,000 as of its most recent filing with the Securities and Exchange Commission. 35.16% of the stock is currently owned by institutional investors.

Insider Buying and Selling at MIRA Pharmaceuticals

In other MIRA Pharmaceuticals news, CEO Erez Aminov sold 55,410 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $1.39, for a total transaction of $77,019.90. Following the completion of the transaction, the chief executive officer now owns 1,105,790 shares in the company, valued at approximately $1,537,048.10. This represents a 4.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.65% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.